Bank of New York Mellon’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.49M | Buy |
282,599
+75,575
| +37% | +$337K | ﹤0.01% | 3121 |
|
|
2026
Q1 | $776K | Buy |
207,024
+3,507
| +2% | +$11.8K | ﹤0.01% | 3366 |
|
|
2025
Q4 | $613K | Sell |
203,517
-16,565
| -8% | -$41.9K | ﹤0.01% | 3497 |
|
|
2025
Q3 | $418K | Buy |
220,082
+4,820
| +2% | +$8.4K | ﹤0.01% | 3694 |
|
|
2025
Q2 | $306K | Buy |
215,262
+201,689
| +1,486% | +$273K | ﹤0.01% | 3791 |
|
|
2025
Q1 | $20.8K | Buy |
+13,573
| New | +$29K | ﹤0.01% | 4088 |
|
|
2024
Q2 | – | Sell |
-232,771
| Closed | -$289K | – | 4122 |
|
|
2024
Q1 | $289K | Sell |
232,771
-49,600
| -18% | -$59.1K | ﹤0.01% | 3790 |
|
|
2023
Q4 | $296K | Buy |
282,371
+39,601
| +16% | +$121K | ﹤0.01% | 3803 |
|
|
2023
Q3 | $1.66M | Buy |
242,770
+344
| +0.1% | +$2.94K | ﹤0.01% | 2908 |
|
|
2023
Q2 | $2.51M | Buy |
242,426
+12,156
| +5% | +$110K | ﹤0.01% | 2711 |
|
|
2023
Q1 | $1.86M | Sell |
230,270
-1,343
| -0.6% | -$17K | ﹤0.01% | 2842 |
|
|
2022
Q4 | $3.65M | Sell |
231,613
-2,269
| -1% | -$36.5K | ﹤0.01% | 2520 |
|
|
2022
Q3 | $3.68M | Buy |
233,882
+31,683
| +16% | +$499K | ﹤0.01% | 2470 |
|
|
2022
Q2 | $2.82M | Buy |
202,199
+16,603
| +9% | +$233K | ﹤0.01% | 2641 |
|
|
2022
Q1 | $3.2M | Sell |
185,596
-726
| -0.4% | -$9.9K | ﹤0.01% | 2676 |
|
|
2021
Q4 | $2.71M | Buy |
186,322
+4,077
| +2% | +$61.8K | ﹤0.01% | 2805 |
|
|
2021
Q3 | $3.28M | Buy |
182,245
+47,003
| +35% | +$754K | ﹤0.01% | 2716 |
|
|
2021
Q2 | $2.38M | Buy |
135,242
+24,086
| +22% | +$547K | ﹤0.01% | 2882 |
|
|
2021
Q1 | $2.8M | Buy |
111,156
+6,537
| +6% | +$128K | ﹤0.01% | 2730 |
|
|
2020
Q4 | $677K | Sell |
104,619
-4,594
| -4% | -$19.4K | ﹤0.01% | 3466 |
|
|
2020
Q3 | $281K | Hold |
109,213
| – | – | ﹤0.01% | 3743 |
|
|
2020
Q2 | $176K | Sell |
109,213
-108,570
| -50% | -$145K | ﹤0.01% | 3824 |
|
|
2020
Q1 | $227K | Sell |
217,783
-1,996
| -0.9% | -$2.72K | ﹤0.01% | 3701 |
|
|
2019
Q4 | $415K | Buy |
219,779
+95,527
| +77% | +$158K | ﹤0.01% | 3683 |
|
|
2019
Q3 | $134K | Sell |
124,252
-40,957
| -25% | -$58.1K | ﹤0.01% | 3979 |
|
|
2019
Q2 | $362K | Sell |
165,209
-39,621
| -19% | -$216K | ﹤0.01% | 3739 |
|
|
2019
Q1 | $1.23M | Buy |
204,830
+6,794
| +3% | +$45K | ﹤0.01% | 3038 |
|
|
2018
Q4 | $1.46M | Sell |
198,036
-223,163
| -53% | -$2.3M | ﹤0.01% | 2893 |
|
|
2018
Q3 | $6.12M | Sell |
421,199
-1,802
| -0.4% | -$30.9K | ﹤0.01% | 2304 |
|
|
2018
Q2 | $8.45M | Buy |
423,001
+31,339
| +8% | +$579K | ﹤0.01% | 2110 |
|
|
2018
Q1 | $6.86M | Buy |
391,662
+119,258
| +44% | +$2.53M | ﹤0.01% | 2184 |
|
|
2017
Q4 | $6.72M | Buy |
272,404
+162,389
| +148% | +$3.95M | ﹤0.01% | 2206 |
|
|
2017
Q3 | $2.84M | Buy |
110,015
+21,754
| +25% | +$583K | ﹤0.01% | 2625 |
|
|
2017
Q2 | $2.39M | Buy |
88,261
+77
| +0.1% | +$2.09K | ﹤0.01% | 2744 |
|
|
2017
Q1 | $2.63M | Sell |
88,184
-26,593
| -23% | -$767K | ﹤0.01% | 2676 |
|
|
2016
Q4 | $3.12M | Buy |
114,777
+68,044
| +146% | +$1.73M | ﹤0.01% | 2589 |
|
|
2016
Q3 | $1.2M | Buy |
46,733
+11,478
| +33% | +$244K | ﹤0.01% | 3072 |
|
|
2016
Q2 | $652K | Buy |
35,255
+19,734
| +127% | +$391K | ﹤0.01% | 3405 |
|
|
2016
Q1 | $294K | Buy |
15,521
+1,238
| +9% | +$23.7K | ﹤0.01% | 3652 |
|
|
2015
Q4 | $385K | Buy |
+14,283
| New | +$278K | ﹤0.01% | 3629 |
|
Other funds holding ACRS
BCM
PAM
TBWA
N
Bank of New York Mellon's ACRS Position: Q2 2026 in Review
Bank of New York Mellon increased its Aclaris Therapeutics (ACRS) stake by 37% in Q2 2026, buying an estimated $337K and bringing the position to 282,599 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #3121.
Bank of New York Mellon first reported a position in ACRS in Q4 2015 and has held it in 40 quarters since. The position peaked at $8.45M in Q2 2018. 52 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.
- Bank of New York Mellon held 282,599 shares of Aclaris Therapeutics worth $1.49M as of Q2 2026.
- Bank of New York Mellon bought 75,575 Aclaris Therapeutics shares in Q2 2026, an estimated $337K.
- Aclaris Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3121 holding.
- Bank of New York Mellon first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 40 quarters since.
- Bank of New York Mellon's Aclaris Therapeutics position peaked at $8.45M in Q2 2018.
- 52 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.